Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM)

Rhea-AI Filing Summary

Cullinan Therapeutics director David D. Meek received a new stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and represents a right to buy the company’s common stock directly.

According to the grant terms, the 25,319-share option will vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting, provided Meek continues to serve as a director through that vesting date. Following this grant, he holds stock options for 25,319 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Meek David D.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,319	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,319 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 25,319 shares Exercise price: $13.55 per share Shares underlying option: 25,319 shares +2 more

5 metrics

Option shares granted 25,319 shares Stock Option (Right to Buy) grant to director

Exercise price $13.55 per share Stock option exercise price

Shares underlying option 25,319 shares Underlying common stock for the option

Options held after grant 25,319 options Total stock options following transaction

Vesting date trigger Earlier of June 16, 2027 or next annual meeting Full vesting condition for option grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 13.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"which shall vest in full on the earlier of (i) June 16, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting financial

"or (ii) the date of the Issuer's next annual meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 05:01 PM Accepted by SEC EDGAR 06/18/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meek David D.

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.55	06/16/2026		A		25,319		(1)	06/16/2026	Common Stock	25,319	$0	25,319	D

Explanation of Responses:

1. The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cullinan Therapeutics (CGEM) director David D. Meek receive in this Form 4?

David D. Meek received a stock option grant for 25,319 shares of Cullinan Therapeutics common stock. The grant is a compensation award and gives him the right to buy shares at a fixed exercise price.

How many Cullinan Therapeutics (CGEM) shares are covered by Meek’s new stock option?

The new stock option covers 25,319 shares of Cullinan Therapeutics common stock. This entire amount was granted in a single award and represents Meek’s reported option holdings following the transaction.

What is the exercise price of David D. Meek’s Cullinan Therapeutics (CGEM) option grant?

The option grant has an exercise price of $13.55 per share. This is the price at which Meek can purchase Cullinan Therapeutics common stock if and when the option is vested and exercised.

When do David D. Meek’s Cullinan Therapeutics (CGEM) options vest?

The options vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting. Vesting is conditioned on Meek’s continued service as a director through the applicable vesting date.

Is David D. Meek’s Form 4 for Cullinan Therapeutics (CGEM) an open-market stock purchase?

No, the filing reports a stock option grant as compensation, not an open-market purchase. The option was awarded at no cost to Meek, with a fixed $13.55 exercise price for future share purchases.